Ketogenic diet therapy addresses the energy requirements of glaucoma patients and inhibits the inflammatory response by activating the lactate-GPR81 signalling pathway and inhibiting AMPK/NF-κB signalling and NLRP3 inflammasome activation [98]. The gene discussed is NFKB1; the disease is glaucoma.